No Data
No Data
Norinco International Cooperation (000065.SZ) has conducted business negotiations with Hunan Er-Kang Pharmaceutical's Er-Kang Mining on lithium mining.
On July 16, Gelunhui reported that an investor asked Norinco International (000065.SZ) on the investor interaction platform, "Does your company have any business dealings with Hunan Er-Kang Pharmaceutical?" The company responded that in recent years, it has actively developed mining and mining construction business in Nigeria, and has conducted business negotiations on lithium mining with Er-Kang Mining under the umbrella of Hunan Er-Kang Pharmaceutical. At present, no substantive cooperation agreement has been signed.
The Recent Pullback Must Have Dismayed Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267) Insiders Who Own 45% of the Company
Key Insights Insiders appear to have a vested interest in Hunan Er-Kang Pharmaceutical's growth, as seen by their sizeable ownership The top 3 shareholders own 50% of the company Past performance
Investors in Hunan Er-Kang Pharmaceutical (SZSE:300267) From Five Years Ago Are Still Down 54%, Even After 7.5% Gain This Past Week
Statistically speaking, long term investing is a profitable endeavour. But that doesn't mean long term investors can avoid big losses. Zooming in on an example, the Hunan Er-Kang Pharmaceutical Co.,
Erkang Pharmaceutical (300267.SZ): Net profit of 2.9015 million yuan in the first quarter decreased by 88.87% year on year
Gelonghui, April 26 | Erkang Pharmaceutical (300267.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 276 million yuan, down 49.57% year on year; net profit attributable to shareholders of listed companies was 2.9015 million yuan, down 88.87% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - RMB 3.3425 million; basic earnings per share.
Erkang Pharmaceutical (300267.SZ) announced first-quarter results, net profit of 2.9015 million yuan, a decrease of 88.87%
According to the Zhitong Finance App, Erkang Pharmaceutical (300267.SZ) released its report for the first quarter of 2024. The company's revenue was 276 million yuan, a year-on-year decrease of 49.57%. Net profit attributable to shareholders of listed companies was 2.9015 million yuan, a year-on-year decrease of 88.87%. The net loss attributable to shareholders of the listed company after deducting non-recurring profit and loss was $3.342,500. Basic earnings per share were $0.0014.
Erkang Pharmaceutical (300267.SZ) announced its 2023 annual results, with a net loss of 195 million yuan from profit to loss
According to Zhitong Finance App, Erkang Pharmaceutical (300267.SZ) released its 2023 annual results report. During the reporting period, the company achieved operating income of 1,783 million yuan, a year-on-year decrease of 4.67%; net loss attributable to shareholders of listed companies of 195 million yuan, and net profit of 459.44,900 yuan in the same period last year; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 232 million yuan; basic loss per share.
No Data